+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Acute lymphoblastic leukemia (ALL) most often affects children, but it can also occur in adults. It is a fast-growing cancer of the blood and bone marrow, where immature white blood cells called lymphoblasts build up and crowd out healthy cells. Stud...

Search Bar & Filters

Found 49 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating how well protective immunity from routine childhood vaccinations lasts in children and young adults under 21 years old who have been treated for B-cell Acute Lymphoblastic LeukemiaLymphoma B-ALLLy, particularly focusing on those who received the immunotherapy drug blinatumomab. The study aims to find out if immunotherapy affects vaccine protection compared to other chemotherapy treatments and whether revaccination can restore immunity in those with low antibody levels. This observational study compares participants who have received blinatumomab with those who have not. It examines their antibody levels to common childhood vaccines to assess immunity persistence. For those without protective antibody levels, revaccination is given to see if it improves immune response. The study does not involve active treatment but collects data on immunity status and revaccination effects. Participants will be followed for at least six months after completing blinatumomab therapy to measure protective antibody titers. The study records whether revaccination leads to seroconversion, meaning a change from non-protective to protective antibody levels. Researchers collect blood samples and monitor immune responses without altering standard care. The entire study is expected to run until 2029, with ongoing assessments of immunity and vaccine response in this vulnerable population.

Age: 1Year - 23YearsAll Genders
2 locations
P

Actively Recruiting

Researchers are conducting a multinational, multicenter, open-label Phase III study to evaluate the efficacy and safety of Radotinib in adults with chronic phase Philadelphia chromosome-positive chronic myeloid leukemia CP-CML who have experienced failure or intolerance to prior tyrosine kinase inhibitor TKI therapies, including Imatinib. This study aims to understand how Radotinib performs in this patient population where previous treatments have not been successful or tolerated. Participants will receive Radotinib 400 mg orally twice daily for 12 months. Dose adjustments to 600 mg or 400 mg twice daily are permitted if participants experience hematologic or non-hematologic toxicities that resolve within specified time frames. This is a single-arm study with no placebo or comparator group, involving continuous administration of the study drug throughout the treatment period. During the study, participants will be regularly monitored for responses such as major cytogenetic response at 6 months and other outcomes including complete cytogenetic response, major molecular response, overall survival, and progression-free survival up to 24 months. Safety and tolerability will also be assessed. The study enrollment started in 2018 and is expected to complete by mid-2028, with ongoing follow-up to assess long-term outcomes.

Age: 18Years +All GendersPhase 3
18 locations
E

Actively Recruiting

Researchers are evaluating the recommended doses of lisaftoclax and olverembatinib when given together with decitabine in people with advanced Chronic Myeloid Leukemia CML and Philadelphia Chromosome-Positive Acute Myeloid Leukemia Ph AML. The study aims to find safe and biologically effective dose levels and to assess treatment effects on remission rates, disease progression, and survival outcomes. It also explores how olverembatinib affects certain cell pathways and protein expressions related to leukemia. Participants receive decitabine intravenously and lisaftoclax and olverembatinib orally. The study includes two phases in Phase 1, different doses of lisaftoclax will be tested with a small group of participants to identify the best dose. In Phase 2, participants will receive the recommended dose found in Phase 1. The combination therapy is given in cycles, and dosing depends on when participants join the study. During the trial, participants will be monitored for safety and side effects over about one year. Researchers will track treatment responses through blood tests and other assessments to measure remission and disease control. Participants must agree to use contraception during and after the study. The total study period runs until early 2029, with evaluations of safety, treatment effects, and survival outcomes throughout.

Age: 18Years +All GendersPhase 1
1 location
P

Actively Recruiting

Researchers are evaluating the tolerability of OJP-001, a combined therapeutic system that includes photodynamic therapy with OMD-001 and extracorporeal circulation therapies OJE-001 and OJC-001, in patients with adult T-cell leukemialymphoma ATL. The study also aims to find the recommended dose and study the way OMD-001 moves through the body, along with assessing the safety and effectiveness of OJP-001. This is a Phase III clinical trial sponsored by Otsuka Medical Devices Co., Ltd. Japan. In the Phase I part, patients receive a single oral dose of 5-ALA followed by one administration of OJP-001. The 5-ALA dose is increased across four groups from 10 mgkg up to 60 mgkg. In the Phase II part, patients receive both 5-ALA and OJP-001 once a week for six months. The treatment involves the use of a photodynamic system combined with 5-ALA, administered according to the defined dosing schedules. Participants will undergo safety and response evaluations during the first two weeks for Phase I and over 24 weeks for Phase II. The main outcomes measured include dose-limiting toxicities in Phase I and best overall response in Phase II. The study involves monitoring blood levels, physical status, and other health markers to assess treatment effects and safety. Total participation may extend up to six months during the Phase II treatment period.

Age: 20Years - 85YearsAll GendersPhase 1Phase 2
5 locations
P

Actively Recruiting

Researchers are evaluating a combination treatment for adults newly diagnosed with Philadelphia Chromosome-positive acute lymphoblastic leukemia PhALL. This phase 2, single-arm, open-label study explores the safety and effectiveness of combining a third-generation tyrosine kinase inhibitor Olverembatinib, a CD3CD19 bispecific T-cell engager Blinatumomab, and a histone deacetylase inhibitor Chidamide, known as the ABC regimen. The study aims to improve early and deep complete molecular remission rates and overall outcomes for this leukemia subtype, especially in patients with high-risk genetic markers like IKZF1 deletions. Participants will receive treatment in phases over several years. Initially, after pretreatment with glucocorticoid, they undergo one year of induction and consolidation therapy with Olverembatinib, Blinatumomab, and Chidamide following a specific schedule of doses and cycles. This is followed by three years of maintenance therapy using Olverembatinib and Chidamide. After treatment, participants enter a five-year follow-up phase to monitor long-term effects and disease status. Throughout the study, participants will be closely monitored for complete molecular remission at three months and other outcomes such as overall survival, event-free survival, and adverse events over up to five years. Specific genetic subgroups like IKZF1del and IKZF1plus will be assessed for treatment response. Regular clinical evaluations, laboratory tests, and safety assessments are part of the study to track participants health and treatment adherence during this multi-year trial.

Age: 18Years +All GendersPhase 2
1 location
P

Actively Recruiting

Researchers are studying whether the drug mogamulizumab can help prevent adult T-cell leukemialymphoma ATL in people at high risk due to infection with the HTLV-1 virus and immune cell changes. This phase 2 trial focuses on people infected with HTLV-1 who have a higher chance of developing ATL, aiming to see if mogamulizumab reduces the viruss presence in their blood. Participants are assigned to one of two treatment groups receiving mogamulizumab Cohort 1 gets 0.3 mgkg every 12 weeks for 2 doses, and Cohort 2 receives 0.3 mgkg every 6 weeks for 4 doses. The study is non-randomized and unblinded, and treatments are given under medical supervision to evaluate dose effects on viral load reduction. During the study, participants undergo assessments including blood tests to measure the virus level, monitoring of organ function, and safety checks like electrocardiograms. Researchers will primarily measure how much the viral load decreases six months after starting treatment. The study lasts through the treatment period and follow-up, with careful observation to understand mogamulizumabs impact on preventing ATL development.

Age: 18Years +All GendersPhase 2
7 locations
C

Actively Recruiting

Researchers are studying the safety and effectiveness of pirtobrutinib LOXO-305 compared to ibrutinib in adults with chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. The study includes participants who may or may not have received prior treatment for their cancer and focuses on those with specific genetic markers, like 17p deletions, in one part of the trial. This is a phase 3, open-label study sponsored by Loxo Oncology, Inc. Participants receive either pirtobrutinib or ibrutinib as oral treatments. The study has two parts Part 1 compares pirtobrutinib and ibrutinib in a broad group of participants and may last up to six years, while Part 2 evaluates pirtobrutinib alone in treatment-nafve participants with 17p deletions for up to two years. Treatments are taken by mouth, and participants are randomly assigned to treatment groups. During the study, participants will undergo regular assessments to monitor their response to treatment, including checking for complete or partial remission. Researchers will evaluate progression-free survival, overall survival, duration of response, and tolerability over several years. Safety and effectiveness are closely tracked with scheduled visits and tests until data cutoff or disease progression. Participation can last up to six years depending on the study part.

Age: 18Years +All GendersPhase 3
143 locations
P

Actively Recruiting

Researchers are evaluating a drug called ABL001 combined with dasatinib Sprycel4 and prednisone, along with blinatumomab, as a possible treatment for adults with B-cell Acute Lymphoblastic Leukemia that is BCR-ABL positive also called Philadelphia chromosome positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in lymphoid blast crisis. This is a Phase I clinical trial aimed at testing the safety of ABL001 and determining the appropriate dose when used with these other drugs. Biomarker testing from blood and bone marrow samples will be included to better understand how the drug may work. Participants will receive all three drugs ABL001 taken orally daily, dasatinib taken orally once a day per cycle, and prednisone taken orally once a day with tapering and stopping during the second cycle. Blinatumomab will be given by intravenous continuous infusion starting no earlier than the first day of cycle 2 through cycle 6, each cycle lasting 42 days, totaling five cycles. Dose escalation follows a standard scheme to find the recommended dose for future studies. During the study, participants will have blood and bone marrow samples collected to assess biomarkers and evaluate the cancer. Researchers will monitor safety and measure outcomes such as the maximum tolerated dose of ABL001 within 42 days and various remission and response rates at 28, 56, and 85 days. The study involves close monitoring of organ function and patient health throughout treatment, with the overall participation timeline depending on individual treatment cycles and responses.

Age: 18Years +All GendersPhase 1
4 locations
C

Actively Recruiting

Researchers are evaluating a chemotherapy regimen for adolescents and young adults with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia ALL. This Phase 2, single-arm study aims to better understand the safety and effectiveness of this treatment in this specific group. The study drugs include several chemotherapy agents and immunotherapy, all FDA-approved but studied here as a combined regimen. The treatment involves multiple phases such as Steroid Prophase, Induction IA and IB, several Blinatumomab cycles, and Consolidation and Continuation phases. These phases include administration of various drugs like dexamethasone, vincristine, pegaspargase, doxorubicin, cyclophosphamide, cytarabine, mercaptopurine, methotrexate, etoposide, and blinatumomab. Treatments are given in cycles lasting from 3 to 42 days, with intrathecal chemotherapy injections included. After about 2 years of treatment, participants will have an end of treatment visit followed by an 8-year follow-up period. Participants will undergo screening, in-clinic visits, and various tests including blood, urine, saliva tests, X-rays, ECGs, echocardiograms, DEXA scans, and bone marrow biopsiesaspirations. Researchers will monitor treatment completion, treatment-related mortality, toxicity rates, remission rates, measurable residual disease, survival outcomes, and transplantation rates. The entire participation is expected to last about 10 years, with close monitoring of adverse events and long-term outcomes.

Age: 18Years - 51YearsAll GendersPhase 2
1 location
P

Actively Recruiting

Researchers are evaluating the safety and appropriate dosing of a drug called asciminib for adults who have been treated for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph B-ALL. The study focuses on two groups those who have had an allogeneic stem cell transplant alloHCT and those who have received chimeric antigen receptor T cell CAR T therapy. This phase 1 study aims to find the best dose of asciminib to prevent relapse in these patients. Participants will receive asciminib treatment on an outpatient basis after their previous therapy with either alloHCT or CAR T cell therapy. The study includes two experimental groups one for patients post-alloHCT and another for patients post-CAR T therapy. Treatment will be carefully monitored to determine the recommended dose for future studies. During the study, researchers will regularly assess participants health, including survival without relapse and overall survival, for up to 24 months. They will monitor organ function, disease status, and any side effects. Participants progress will be tracked to evaluate the safety and effectiveness of asciminib maintenance therapy over time.

Age: 18Years +All GendersPhase 1
1 location

1-10 of 49

1